The complement component C5 inhibitory peptide zilucoplan is currently in phase III clinical trials for myasthenia gravis (MG). Despite being at an advanced stage of clinical development, there have been no published reports in the literature detailing its chemical synthesis. In this work, we describe an approach for the chemical synthesis of zilucoplan and validate that the synthesised compound blocks LPS-induced C5a production from human blood.

中文翻译：

---

补体 C5 抑制肽 zilucoplan 的化学合成和表征

补体成分 C5 抑制肽 zilucoplan 目前正处于重症肌无力 (MG) 的 III 期临床试验阶段。尽管处于临床开发的后期阶段，但在文献中还没有详细介绍其化学合成的已发表报告。在这项工作中，我们描述了 zilucoplan 的化学合成方法，并验证合成的化合物可以阻止 LPS 诱导的人血 C5a 产生。